Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unpacking The $2.2Tn Stimulus Act: Boosts To Medtech And Diagnostics To Fight Coronavirus

Executive Summary

A $2.2tn coronavirus stimulus package signed into law by President Trump on 27 March will distribute billions of dollars to federal agencies – including the FDA, the CDC and the FEMA – to hasten approvals of new diagnostics, medical ventilators, respirators and other medtech supplies, conduct more testing of potential COVID-19 patients, and quickly distribute medical supplies where needed most.

You may also be interested in...



FDA Introduces ‘Proactive‘ Resilient Supply Chain Program To Reduce Future Device Shortages

The US FDA’s Resilient Supply Chain Program (RSCP) will be housed in the agency’s Office of Strategic Partnerships and Technology Innovation and aims to reduce future supply chain shortages by applying lessons learned during the pandemic.

Congressional Action Needed To Protect Device Supply Chain, FDA’s Woodcock Says

The US FDA needs enhanced authorities as well as increased funding to track and prevent device shortages, acting commissioner Janet Woodcock argues.

US House Energy & Commerce Committee Lays Out Medtech Agenda, Membership, For 2021 Congress

The House E&C committee and its subpanels will address coronavirus testing, FDA device regulation and cybersecurity during the upcoming 117th Congress.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT126482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel